Klinik I für Innere Medizin, Center for Integrated Oncology Köln Bonn, Universität zu Köln, Joseph-Stelzmann Str. 9, 50924 Köln, Germany.
Best Pract Res Clin Haematol. 2010 Mar;23(1):85-96. doi: 10.1016/j.beha.2009.12.002.
Rapid progress has been achieved recently in the management of chronic lymphocytic leukaemia (CLL). New insights into the molecular pathology of CLL have generated a plethora of biological markers that predict the prognosis and influence therapeutic decisions. Moreover, fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab, have been approved by European and/or American regulatory agencies. Additional monoclonal antibodies targeting CD20, CD23, CD37, CD38 or CD40, as well as drugs designed to interfere with proteins regulating the cell cycle, apoptotic machinery or leukaemic microenvironment (e.g., flavopiridol, oblimersen, ABT-263 or lenalidomide) are investigated in clinical trials. An increased experience with reduced-intensity allogeneic progenitor cell transplantation allows offering this option to physically fit patients. This review attempts to summarise the current use of these different modalities in CLL therapy.
近年来，慢性淋巴细胞白血病（CLL）的治疗取得了快速进展。对 CLL 分子病理学的新认识产生了大量生物标志物，这些标志物可预测预后并影响治疗决策。此外，氟达拉滨、苯达莫司汀和两种单克隆抗体，阿仑单抗和利妥昔单抗，已被欧洲和/或美国监管机构批准。其他针对 CD20、CD23、CD37、CD38 或 CD40 的单克隆抗体以及旨在干扰调节细胞周期、凋亡机制或白血病微环境的蛋白质的药物（如 flavopiridol、oblimersen、ABT-263 或来那度胺）正在临床试验中进行研究。随着减强度异基因祖细胞移植经验的增加，为身体状况良好的患者提供了这种选择。本综述试图总结这些不同方法在 CLL 治疗中的当前应用。
